Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB

We report a first case of using a 5α-reductase inhibitor (5ARI) and combined androgen blockade (CAB) as a cytoreductive regimen before prostate brachytherapy. Prostate volume reduction with CAB is limited to approximately 40% in most cases, making it difficult to meet anatomical constraints to perfo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Am J Clin Exp Urol
Главные авторы: Muro, Yusuke, Kosaka, Takeo, Mizuno, Ryuichi, Ohashi, Toshio, Shigematsu, Naoyuki, Oya, Mototsugu
Формат: Artigo
Язык:Inglês
Опубликовано: e-Century Publishing Corporation 2015
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4446383/
https://ncbi.nlm.nih.gov/pubmed/26069888
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы